Ignite Creation Date:
2024-05-06 @ 1:46 PM
Last Modification Date:
2024-10-26 @ 1:19 PM
Study NCT ID:
NCT04113616
Status:
TERMINATED
Last Update Posted:
2024-03-22
First Post:
2019-10-01
Brief Title:
An Open-Label Multicenter Phase 1b2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine LDAC or Decitabine in Patients With Acute Myeloid Leukemia AML
Sponsor:
Organization:
Kartos Therapeutics Inc
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
70
Enrollment Type:
ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE1 |
| PHASE2 |
Observational Models:
Time Perspective List:
Who Masked List: